Skip to main content
Clinical Trials/NCT00325598
NCT00325598
Completed
Phase 1

Partial Breast Irradiation (PBI) for Selected Patients With Early Breast Cancer: A Phase I/II Feasibility Study

Washington University School of Medicine1 site in 1 country100 target enrollmentFebruary 14, 2006

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Breast Neoplasms
Sponsor
Washington University School of Medicine
Enrollment
100
Locations
1
Primary Endpoint
Feasibility of PBI Directed External Radiotherapy as Measured by Development of Histological Fat Necrosis or Other Grade 4 Skin or Grade 4 Subcutaneous Toxicity, or Requires Surgery for the Skin/Subcutaneous Toxicity
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

This study investigates the feasibility and safety of delivering radiation therapy only to part of the breast, (the tumor bed and selected areas) rather than the whole breast, for patients with early stage breast cancer.

Registry
clinicaltrials.gov
Start Date
February 14, 2006
End Date
April 16, 2017
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Feasibility of PBI Directed External Radiotherapy as Measured by Development of Histological Fat Necrosis or Other Grade 4 Skin or Grade 4 Subcutaneous Toxicity, or Requires Surgery for the Skin/Subcutaneous Toxicity

Time Frame: Within 1 year of protocol registration

-The study will be deemed infeasible if more than 4 patients develop histological fat necrosis or other grade 4 skin or grade 4 subcutaneous toxicity, or requires surgery for her skin or subcutaneous toxicity

Feasibility of PBI Directed External Radiotherapy as Measured by Percentage of Participants Achieving a Dosimetrically Satisfactory Treatment Plan

Time Frame: Within 1 year of protocol registration

-The study will be deemed infeasible if more than 4 patients cannot be given treatment because her tumor is such that a dosimetrically satisfactory treatment plan cannot be devised for her.

Secondary Outcomes

  • Local Control Rate(Up to 5 years)
  • Distant Control Rate(Up to 5 years)
  • Incidence and Severity of Cutaneous Toxicity(Up to 5 years)
  • Incidence of Fat Necrosis(Up to 5 years)
  • Incidence of Breast Fibrosis(Up to 5 years)
  • Cosmetic Outcome(Up to 5 years)
  • Regional Control Rate(Up to 5 years)

Study Sites (1)

Loading locations...

Similar Trials